Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling

Jiahui Wu,Xiao He,Ziwei Xiong,Lingyu Shi,Daofeng Chen,Yulin Feng,Quan Wen

DOI: https://doi.org/10.3389/fonc.2024.1515205

IF: 4.7

2024-12-04

Frontiers in Oncology

Abstract:This article is a correction to: Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling

oncology

What problem does this paper attempt to address?

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Wenxing Chen,Yanhong Pan,Siliang Wang,Yuping Liu,Guangying Chen,Liang Zhou,Chao Zhang,Wenting Ni,Aiyun Wang,Yin Lu,Shile Huang

DOI: https://doi.org/10.1186/s12885-019-5458-y

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Following publication of the original article [1], the author noticed the following errors in the article.
Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling

Jiahui Wu,Xiao He,Ziwei Xiong,Lingyu Shi,Daofeng Chen,Yulin Feng,Quan Wen

DOI: https://doi.org/10.3389/fonc.2022.855603

IF: 4.7

2022-04-08

Frontiers in Oncology

Abstract:Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) protein serve as a critical pillar in the treatment of non-small cell lung cancer (NSCLC), but resistance is universal. Identifying the potential key factors of drug resistance to EGFR-TKIs is essential to treat patients with EGFR mutant lung cancer. Our research here shows that bruceine H suppressed the proliferation, migration, and invasion of lung cancer cells; inhibited the growth of human NSCLC cell xenografts; and enhanced the therapeutic effects of gefitinib in the PC-9/GR xenograft models, possibly by inhibiting Notch3. In order to analyze the potential targets of the combination of Notch3 and EGFR-TKIs on resistance to EGFR, we analyzed the differences of gene expression between NSCLC tissues and EGFR-driven gefitinib-resistant tumoral groups and then identify through the WGCNA key genes that may provide therapeutic targets for TKI-resistant lung cancer xenograft models. We confirmed that EGFR-TKI in combination with Notch3 inhibitor can inhibit the expression of β-catenin and enhance the level of FOXO3a, leading to improved recurrence-free survival and overall survival of the xenotransplantation model. These results support that the combination of gefitinib and bruceine H may provide a promising alternative strategy for treating acquired EGFR-TKI resistance in patients with NSCLC.

oncology
Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Xiu-Ying He,Yang Xu,Qing-Jie Xia,Xiao-Ming Zhao,Shan Li,Xiao-Qiong He,Ru-Rong Wang,Ting-Hua Wang

DOI: https://doi.org/10.3389/fonc.2022.872110

IF: 4.7

2022-03-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.663262.].

oncology
Corrigendum: 5-Demethylnobiletin mediates cell cycle arrest and apoptosis via the ERK1/2/AKT/STAT3 signaling pathways in glioblastoma cells

Xuehua Zhang,Leilei Zhao,Jinlong Xiao,Yudi Wang,Yunmeng Li,Chaoqun Zhu,He Zhang,Yurui Zhang,Xiao Zhu,Yucui Dong

DOI: https://doi.org/10.3389/fonc.2024.1494738

IF: 4.7

2024-10-01

Frontiers in Oncology

Abstract:This article is a correction to: 5-Demethylnobiletin mediates cell cycle arrest and apoptosis via the ERK1/2/AKT/STAT3 signaling pathways in glioblastoma cells

oncology
Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Chun-shuang Ma,Qian-ming Lv,Ke-ren Zhang,Ya-bin Tang,Yu-fei Zhang,Ying Shen,Hui-min Lei,Liang Zhu

DOI: https://doi.org/10.1038/s41401-023-01131-5

IF: 7.169

2023-08-02

Acta Pharmacologica Sinica

Abstract:Acta Pharmacologica Sinica, Published online: 01 August 2023; doi:10.1038/s41401-023-01131-5 Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

pharmacology & pharmacy,chemistry, multidisciplinary
Corrigendum: Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis

Ganping Wang,Yarong Dai,Kang Li,Maosheng Cheng,Gan Xiong,Xiaochen Wang,Shuang Chen,Zhi Chen,Jianwen Chen,Xiuyun Xu,Rong-song Ling,Liang Peng,Demeng Chen

DOI: https://doi.org/10.3389/fcell.2021.675417

IF: 5.5

2021-03-24

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2021.627706.].

cell biology,developmental biology
Corrigendum: GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT–Mediated EMT

En Xu,Xuefeng Xia,Chaoyu Jiang,Zijian Li,Zhi Yang,Chang Zheng,Xingzhou Wang,Shangce Du,Ji Miao,Feng Wang,Yizhou Wang,Xiaofeng Lu,Wenxian Guan

DOI: https://doi.org/10.3389/fcell.2022.841792

IF: 5.5

2022-01-01

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2020.591239.].
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne P. Robichaux,Yasir Y. Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach

DOI: https://doi.org/10.1038/s41591-024-03178-1

IF: 82.9

2024-08-22

Nature Medicine

Abstract:Nature Medicine, Published online: 20 August 2024; doi:10.1038/s41591-024-03178-1 Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

biochemistry & molecular biology,cell biology,medicine, research & experimental
N6 -methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming: Erratum

Zhuojia Chen,Long Wu,Jiawang Zhou,Xinyao Lin,Yanxi Peng,Lichen Ge,Cheng-Ming Chiang,Hui Huang,Hongsheng Wang,Weiling He

DOI: https://doi.org/10.7150/thno.85930

IF: 11.6

2023-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.40144.].

medicine, research & experimental
Correction: Corrigendum: Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Yifeng Xia,Narayana Yeddula,Mathias Leblanc,Eugene Ke,Yonghui Zhang,Eric Oldfield,Reuben J. Shaw,Inder M. Verma

DOI: https://doi.org/10.1038/ncb3145

IF: 21.3

2015-01-01

Nature Cell Biology

Abstract:Nat. Cell Biol. 14, 257–265 (2012); published online 12 February 2012; corrected after print 26 February 2015 The version of this Article originally published should have acknowledged that this work was also supported by NIH grant number CA158191. This has been corrected in all online versions of the Article.
Erratum: CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway: Erratum.

Yan-Ming Liu,Yue Cao,Ping-Sen Zhao,Liang-Yin Wu,Ya-Min Lu,Yu-Long Wang,Jia-Feng Zhao,Xin-Guang Liu

DOI: https://doi.org/10.7150/ijbs.72651

2022-01-01

International Journal of Biological Sciences

Abstract:[This corrects the article DOI: 10.7150/ijbs.66915.].
Corrigendum: AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer

Kaiming Zhang,Peng Liu,Hailin Tang,Xiaoming Xie,Yanan Kong,Cailu Song,Xingsheng Qiu,Xiangsheng Xiao

DOI: https://doi.org/10.3389/fphar.2020.01107

IF: 5.6

2020-07-20

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2018.01248.].

pharmacology & pharmacy
Author Correction: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness

Ming-Jenn Chen,De-Wei Wu,Yao-Chen Wang,Chi-Yi Chen,Huei Lee

DOI: https://doi.org/10.1038/s41598-020-74206-6

IF: 4.6

2020-10-23

Scientific Reports

Abstract:An amendment to this paper has been published and can be accessed via a link at the top of the paper.

multidisciplinary sciences
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Correction to: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway

Cheng-Cao Sun,Wei Zhu,Shu-Jun Li,Wei Hu,Jian Zhang,Yue Zhuo,Han Zhang,Juan Wang,Yu Zhang,Shao-Xin Huang,Qi-Qiang He,De-Jia Li

DOI: https://doi.org/10.1186/s13073-021-00834-w

IF: 15.266

2021-02-11

Genome Medicine

Abstract:An amendment to this paper has been published and can be accessed via the original article.

genetics & heredity
Corrigendum: Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway

Jida Guo,Shengqiang Zhang,Jun Wang,Pengfei Zhang,Tong Lu,Linyou Zhang

DOI: https://doi.org/10.3389/fonc.2022.970020

IF: 4.7

2022-07-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.833719.].

oncology
Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC

Junchao Cai,Lishan Fang,Yongbo Huang,Rong Li,Xiaonan Xu,Zhihuang Hu,Le Zhang,Yi Yang,Xun Zhu,Heng Zhang,Jueheng Wu,Yan Huang,Jun Li,Musheng Zeng,Erwei Song,Yukai He,Li Zhang,Mengfeng Li

DOI: https://doi.org/10.1038/ncomms16196

IF: 16.6

2018-01-01

Nature Communications

Abstract:Nature Communications 8: Article number: 15870 (2017); Published online 19 June 2017; Updated 30 March 2018 In the original version of this Article, the affiliation details for Yan Huang and Li Zhang were incorrectly given as ‘Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China’, and should have been ‘State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China’.

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Corrigendum: 5-Demethylnobiletin mediates cell cycle arrest and apoptosis via the ERK1/2/AKT/STAT3 signaling pathways in glioblastoma cells

Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Corrigendum: Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis

Corrigendum: GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT–Mediated EMT

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

N6 -methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming: Erratum

Correction: Corrigendum: Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Erratum: CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway: Erratum.

Corrigendum: AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer

Author Correction: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Correction to: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway

Corrigendum: Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway

Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC